Trial
NCT02427893
Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Genentech, Inc.
Condition
Melanoma
Intervention
Cobimetinib
Why stopped
no patients were enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-11-15